Immupharma (IMM)

 

Latest News

Holding(s) in Company

RNS Number: 5795L Immupharma PLC 20 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma plc 1b...

Holding(s) in Company

RNS Number: 4403L Immupharma PLC 19 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma plc 1b...

FTSE follows US higher

The FTSE 100 was lifted by a raft of positive financial results and a strong performance in the US overnight, helping the b...

ImmuPharma's Lupuzor fails to meet primary endpoint in phase III trial

ImmuPharma said Tuesday its pivotal Phase III trial of lupus treatment Lupuzor failed to meet the trial's primary endpoin...

All News

DateHeadlineSource
20-04-18Holding(s) in CompanyRNS
19-04-18Holding(s) in CompanyRNS
17-04-18FTSE follows US higherStockMarketWire
17-04-18ImmuPharma's Lupuzor fails to meet primary endpoint in phase III trialStockMarketWire
17-04-18Topline results of Lupuzor Pivotal Phase III TrialRNS
28-03-18Appointment of Joint BrokerRNS
23-03-18ImmuPharma to reveal Lupuzor top line results by mid-AprilStockMarketWire
23-03-18Lupuzor Pivotal Phase III Study UpdateRNS
05-03-18AIM Notice (17)RNS
15-02-18London Investor EveningRNS
09-02-18Holding(s) in CompanyRNS
07-02-18Holding(s) in CompanyRNS
05-02-18Holding(s) in CompanyRNS
02-02-18Six AIM pharma shares on verge of breakthroughInteractive Investor
31-01-18Holding(s) in CompanyRNS
24-01-18ImmuPharma raises £10mStockMarketWire
24-01-18Successful Placing to Raise ?10 MillionRNS
18-01-18Completion of LupuzorT Pivotal Phase III StudyRNS
21-12-17ImmuPharma completes dosing in Lupuzor study StockMarketWire
21-12-17Grant of OptionsRNS
21-12-17Last patient completes dosing in LupuzorT TrialRNS
12-12-17Broker Forecast - finnCap issues a broker note on ImmuPharma PLCStockMarketWire
28-11-17Holding(s) in CompanyRNS
24-11-17Grant of OptionsRNS
02-11-17Lupuzor trial on track, says ImmuPharma StockMarketWire
02-11-17Update on LupuzorT Pivotal Phase III StudyRNS
16-10-17Holding(s) in CompanyRNS
04-10-17ImmuPharma completes sharing agreement with Lanstead StockMarketWire
04-10-17Completion of Lanstead Sharing AgreementRNS
27-09-17ImmuPharma revenues riseStockMarketWire
27-09-17Interim ResultsRNS
26-09-17Preparation of Lupuzor'sT Regulatory SubmissionsRNS
21-09-17Update on LupuzorT Pivotal Phase III StudyRNS
19-09-17ImmuPharma schedules interims StockMarketWire
19-09-17Notification of Interim ResultsRNS
18-08-17AIM Rule 17 NoticeRNS
12-07-17Grant of OptionsRNS
30-06-17Result of AGMRNS
30-06-17Broker Forecast - Northland Capital issues a broker note on ImmuPharma PLCStockMarketWire
30-06-17Update on LupuzorT Pivotal Phase III StudyRNS

RSS feeds

  • Editorial news feed for LSE:IMM Editorial
  • Regulatory news feed for LSE:IMM Regulatory
Our secure site will be unavailable this Sunday (22nd) from 6am until the evening. Sorry for any inconvenience.